NCT03275740 - A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2017

Primary Completion Date

January 6, 2023

Study Completion Date

January 6, 2023

Conditions

HealthyPrimary Immune ThrombocytopeniaPolyradiculoneuropathy, Chronic Inflammatory Demyelinating

Interventions

DRUG

PF-06755347 intravenous healthy participant

Single doses of PF-06755347 will be administered intravenously dose levels 1, 2, 3, 4, 5, and 6.

DRUG

Placebo intravenous healthy participant

Placebo comparator

DRUG

PF-06755347 subcutaneous healthy participant

single doses of PF-06755347 will be administered subcutaneously at dose levels of SC1, SC2, SC3, SC4, and SC5.

DRUG

Placebo subcutaneous healthy participant

placebo comparator

DRUG

PF-06755347 subcutaneous ITP

single doses of PF-06755347 will be administered subcutaneously at 2 dose levels tested in healthy participants

Trial Locations (6)

NZCR (New Zealand Clinical Research) OPCO Limited, Christchurch

Hospital Universitario La Paz, Madrid

Hospital Universitario Virgen del Rocío, Seville

Pfizer New Haven Clinical Research Unit, New Haven

Pfizer Clinical Research Unit, Brussels

Hammersmith Medicines Research (HMR), London